Resonance Health

Be Better Informed

"Expanded capabilities, improved commercial outcomes"

2022

INVESTOR PRESENTATION

24 November 2022

DISCLAIMER

This presentation has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward-looking statements are not guarantees of future performance, and involve risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment. The information in this presentation does not account for the objectives, financial situation or needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision.

To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other persons, accept any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it.

CORPORATE INFORMATION

Resonance Health
Be Better Informed

Resonance Health provides medical devices and services for non-invasive assessment of organ health. We accurately assess organ-iron and organ-fat, and other organ-biomarkers. Our services are used by clinicians and patients globally, facilitating interventions that can slow, stop, or reverse disease progression.

Pharma use our regulatory-cleared and research-use software-medical-devices and ISO compliant central lab services in their clinical drug trials. Better organ health, enabled by non-invasive, affordable organ-assessment will save billions in healthcare costs and improve and extend the lives of people globally.

FOLLOW US

/Resonance-Health-Ltd /ResonanceHealth /ResonanceHealthLtd

"Enhancing shareholder value through commercialising new work streams, innovating our services to enhance their marketability and usability, and investing sensibly in high-impact R&D"

Martin Blake, Chairperson

Shareholder Information	
ASX Code:	RHT
Ordinary Shares on Issue:	461.1M
Market Cap (at SP $0.07):	$32.3M
Enterprise Value (at SP $0.07):	$25.3M
Board + Management Holding:	20.1%
Top 20 Shareholders:	40.7%

Management Team	
Managing Director:	Mr Mitchell Wells
COO + CFO:	Mr Nick Allan
CSO Imaging + AI:	Dr Wenjie Pang
CSO Molecular Medicine:	Dr Sherif Boulos
GM Quality + Regulatory:	Ms Virginia Atkinson
GM Innovation + Projects:	Mr Chad Tondut
GM BD + Clinical Engagement:	Dr Sofie De Meyer
Chief Technology Officer:	Mr Ben Winters

THE WHY – ENDEMIC LIVER DISEASE

Resonance Health
Be Better Informed

LIVER DISEASES

Fatty Liver Disease

Associated with obesity, diabetes, hypertension.
25% of global population*

Iron Overload Diseases

250M haemoglobin disease gene carriers **400K carrying infants born globally p/a***

Liver Cancer (HCC)

4th most common cause of cancer death **906K new cases + 830K deaths globally p/a***

Causes of Liver Disease

Genetics, obesity, alcohol consumption, iron-overload viral infections, lifestyle

GROWTH IN LIVER DISEASE MORTALITY



PROGRESSION OF LIVER DISEASES



"Liver disease is a leading cause of death worldwide and a huge burden on global health systems, but many liver diseases can be reversed with early intervention, which is possible using non-invasive imaging analysis methods and blood biomarkers to guide patient detection and staging of severity of liver fibrosis". Prof. John Olynyk, Chief Medical Officer

THE HOW – LIVER ASSESSMENT

RESONANCE HEALTH		
		
CENTRAL (DRY-LAB) SERVICES*	**CLINICAL TRIAL SERVICES**	**CENTRAL (WET-LAB) SERVICES***
IMAGING MEDICAL DEVICES	**CRO TRIAL MANAGMENT**	**BIOMEDICAL ANALYSIS**
• 6 regulatory cleared medical devices • >80,000 patient reports provided • Reimbursement in key markets • Over 50 clinical studies serviced	• Decades of experience in clinical trials • Increasing demand for CRO services • Capitalise on expanding marketplace • Australia increasingly sought for trials	• New wet-lab established in Perth WA • Consolidation of labs into single lab • Monetising molecular medicine R&D • New equipment installation in progress

**See description of dry and wet labs at Annex A*

"Resonance Health improves and extends lives by providing outstanding service provision in (i) medical imaging analysis (ii) biomedical laboratory analysis, and (iii) CRO trial management to pharmaceutical companies; expanded capabilities for improved commercial outcomes."

Mitchell Wells, Managing Director

IMAGING ANALYSIS (DRY-LAB) SERVICES

Resonance Health
Be Better Informed

CORE LAB SERVICE

FerriScan®

- Analyses liver-iron-concentration
- Global gold standard for liver iron
- >70,000 patient reports delivered
- CE Marked and ARTG Listed
- US FDA regulatory cleared

CardiacT2*

- Analyses cardiac (heart) iron
- Most widely used method for this
- >20,000 patient reports delivered
- CE Marked and ARTG Listed
- US FDA regulatory cleared

HepaFat-Scan®

- Analyses liver fat + distribution
- Maps and quantifies fat metrics
- ISO compliant central lab analysis
- CE Marked and ARTG Listed
- US FDA regulatory cleared

LiverScan

- Analyses liver-iron and liver-fat
- Combines FerriScan + HepaFat
- ISO compliant central lab analysis
- CE Marked and ARTG Listed
- US FDA regulatory cleared

OrganVolume

- Analyses organ volume using MRI
- Standardized across MRI models
- Application to drug clinical trials
- ISO compliant central lab analysis
- US FDA regulatory cleared

BoneMarrowR2

- Analyses bone marrow iron level
- Standardized across MRI models
- Application to marrow transplant
- ISO compliant central lab analysis
- US FDA regulatory cleared

ARTIFICIAL INTELLIGENCE

FerriSmart®

- Analyses liver-iron-concentration
- AI assisted for rapid assessment
- Calibrated using FerriScan
- CE Marked and ARTG Listed
- US FDA regulatory cleared

HepaFat-AI®

- Analyses liver fat + distribution
- AI assisted for rapid processing
- Also provides steatosis grading
- CE Marked and ARTG Listed
- US FDA regulatory cleared

LiverSmart®

- Analyses liver-iron and live- fat
- AI assisted for rapid processing
- Combines FerriSmart + HeapF-AI
- US CPT code for reimbursement
- US FDA regulatory cleared

"Resonance Health's medical imaging analysis services and software-medical-devices are widely used in clinical diagnosis and management by clinicians, and by pharma in trials seeking new drugs and methods to treat diseases including NAFLD which affects around 30% of the global population, and blood diseases affecting millions of people.

Fatty liver disease is endemic, and there is a race-on for new drug treatments to address it. Our artificial intelligence (AI) enabled solutions can deliver medical image analysis results instantly and improve hospital and radiology workflow with better patient outcomes."

Dr Wenjie Pang – Chief Scientific Officer

IMAGING ANALYSIS (DRY-LAB) SERVICES

Resonance Health
Be Better Informed

RESEARCH SERVICES

OrganFe-Scan

- Analyses organ-iron using MRI
- Including brain, kidney, pancreas
- ISO compliant central lab analysis
- Application to drug clinical trials

OrganFat-Scan

- Analyses organ-fat using MRI
- Including pancreas and spleen
- ISO compliant central lab analysis
- Application to drug clinical trials

Our organ-scan services are for investigational-use only, used as research tools in studies. Depending on customer needs we can tailor the acquisition protocol to suit the organ.

MRI CALIBRATION DEVICES

T1CMR Phantom

- T1MES phantom for T1+ECV map
- Used to correctly calibrate MRI
- Standardized across MRI models
- Application to drug clinical trials
- US FDA cleared + CE Marked

T2CMR Phantom

- T2MES phantom for T2+ECV map
- Used to correctly calibrate MRI
- Standardized across MRI models
- Application to drug clinical trials
- Experimental and research use

We manufacture phantoms for calibrating MR machines, quality assured under ISO 13485:2016 for medical devices. Other tailor-made phantom products can be manufactured on request.



CLINICAL TRIAL MANAGEMENT + CRO SERVICES

Resonance Clinical

TRIAL CRO — DRY-LAB — WET-LAB

PHARMA — IMAGING — BIOMEDICINE

"Resonance Clinical is a new commercial initiative aimed at the lucrative and expanding global clinical trial marketplace, especially for the treatment of liver diseases such as NAFLD, which affects up to 30% of the world population.

Through leveraging our scientific and clinical credentials in drug development we aim to deliver a high-level service to new and existing clients of Resonance Health."

Dr Sherif Boulos, Project Director-Resonance Clinical

Resonance Clinical provides objective, reproducible, and quantitative CRO services for multi-national and multi-center clinical trials. From trial design and study protocol development to project management and monitoring, our experienced team provides end-to-end solutions.

- Clinical trial management
- Trial Protocol development
- Data management + biostatistics
- Medical safety + pharmacovigilance
- Medical affairs + communications
- Quality assurance + regulatory
- Clinical operations + central lab services

+18	+250	+53
YEARS	SITES	COUNTRIES

BIOMEDICAL CENTRAL (WET-LAB) SERVICES

Resonance Clinical
Powered by Resonance Health



CENTRAL WET-LAB

From biomarkers to genotyping the new Central Wet-Lab will provide a range of clinical and pre-clinical services, including:

- **Sample reception, tracking and storage**
- **Post collection processing of urine, blood, plasma, serum + tissue**
- **Comprehensive list of biomarker assays + customised assays**
- **Genotyping, sequencing, mutation + copy number analysis**
- **Target specific mRNA/protein expression analysis**
- **Existing MRI imaging calibration Phantom production**

In addition, we can partner with 3rd party pathology services for sample collection and safety assessments in clinical trial work.

"In addition to standard biochemical + novel biomarker endpoints, our central wet-lab can offer disease associated panels for:

- ***Liver Disease***
- ***Haematology***
- ***Metabolic, Obesity + Diabetes***
- ***Reproductive Endocrinology***
- ***Oncology***
- ***Neurology***
- ***Inflammation***
- ***Viral Disease"***

Dr Sofie De Meyer, GM – BD + Clinical Engagement

www.resonanceclinical.com

R&D + INNOVATION - VALUE INFLECTION POINTS



"Since releasing to the market our 3T MRI machine FerriScan 60 days ago, almost 50 new MRI machines have registered for services. The dual FerriScan and CardiacT2 package has become the standard of care in the UK, creating an immediate need for CardiacT2* calibration on 3T. We are now validating CardiacT2*, and FerriSmart, for 3T MRI scanners and we expect to finalize this by the end of the year."*

Chad Tondut – GM Innovation + Development

R&D + INNOVATION - VALUE INFLECTION POINTS

FibrosisAssessment

Proof of Concept	Discovery + IP Protection	Multi-Centre Clinical Validation	Regulatory Clearances	Commercialisation

Completed

"Resonance Health is working towards a non-invasive and standardized best-in-class assessment of liver fibrosis. Liver fibrosis aligns perfectly with our liver assessment services and with this capability we will have a truly holistic liver assessment service for clinicians and patients globally." Dr Wenjie Pang, Chief Scientific Officer

LungSmart

Powered by Resonance Health

FOR CYSTIC FIBROSIS AND PULMONARY EMBOLISM

AI assisted medical-software that identifies, categorizes and quantifies lung conditions including cystic fibrosis and its comorbidities and pulmonary embolism (PE), a potentially lethal blood blockage.

PE is a major cause of death, with 900K deaths p.a. in the USA alone from PE which equates to 1-2 per 1000 deaths. Preliminary discussions have been held with possible commercial collaborators active in lungs.



Proof of Concept	Model Development	Multi-Centre Clinical Validation	Regulatory Clearances	Commercialisation

Completed

R&D + INNOVATION - VALUE INFLECTION POINTS

BloodMarkerProject

The Company is developing novel blood markers with the potential to provide cost-effective assessments of iron-overload and liver-health for use in countries with limited access to MRI machines and/or when frequent cost-effective monitoring is warranted. The R&D team is analysing a combined validation set of blood samples taken from 150+ Vietnamese and Turkish patients with either Thalassemia or other iron overload disorders. In preliminary work-to-date, the results support the findings from the original discovery project. This biomarker validation work is continuing and is scheduled for completion in Q1 2023.

ASONProject

The molecular medicine ASO (antisense oligonucleotide) R&D team has established research collaborations with The Liver Cancer Group and the Alzheimer's Disease Research Group at Curtin University. Work on the liver cancer project aims to investigate if the ASOs can suppress human cancer cell growth in a pre-clinical animal model of Hepatocellular carcinoma (HCC). In the Alzheimer's disease project, an ASO developed to increase neuronal survival, will be tested in a mouse model of Alzheimer's disease. In-house testing of this novel ASO in various neuronal cell disease models is expected to generate data relevant to other serious brain disorders such as Parkinson's disease (PD), Traumatic Brain Injury (TBI) and motor neuron disease (MND).



FY2022 HIGHLIGHTS

Clinical Trials

- Clinical trials valued at A$2.1M contracted including first service contract for HepaFat-AI
- Entered China through first pharma service contract signed with a Chinese pharma
- **Post Period:** contracted for two new clinical trials with combined value of A$1.5m

Imaging Services Partnerships

- AI distribution agreement signed in India enabling entry into the very large Indian market
- Partnered with Thalassaemia International Federation (TIF) for FerriSmart in new markets
- Channel partners and distribution networks for AI assisted services reinvigorated

Product development + R&D

- LiverSmart, iron and fat analysis, developed and US FDA regulatory clearance obtained
- CPT code eligibility confirmed for LiverSmart, a key reimbursement milestone in the US
- Two new PCT patent applications filed for novel approaches in molecular medicine R&D

Team + Strategy

- Business Development and Sales personnel appointed in existing and key new markets
- Initiated studies investigating clinical benefits of FerriSmart + LiverSmart in patient outcomes
- **Post Period:** Resonance Clinical initiative launched targeting prolific global clinical trial market

"Expanded capabilities, improved commercial outcomes"

Resonance Health

Be Better Informed

FOLLOW US

/Resonance-Health-Ltd /ResonanceHealth /ResonanceHealthLtd

WWW.RESONANCEHEALTH.COM WWW.RESONANCECLINICAL.COM

141 Burswood Rd Burswood
WA 6100
Australia

+ 61 892865300

info@resonancehealth.com

APPENDIX – DESCRIPTION OF DRY + WET LAB



Source: https://universitylabpartners.org/

APPENDIX - GLOBAL PREVALENCE OF DISEASES

MAIN DISEASE FOCUS AREAS

PREVALENCE OF IRON-OVERLOARD DISEASES



*Source: World Distribution, Population Genetics and Health Burden of the Hemoglobinopathies. Thomas N Williams and David J Weatherall, Cold Spring Harb Perspect Med 20122:a011692

- 250M gene carriers of haemoglobin disease
- 400K infants born p/a with haemoglobin disease

PREVALENCE OF FATTY LIVER + CARDIOVASCULAR DISEASES



*Source: Nonalcoholic fatty liver disease and cardiovascular diseases phenotypes, Giandomenico Bisaccia et al, SAGE Open Medicine Volume 8: 1–15, 21 May 2020

- 1 billion worldwide with fatty-liver-disease
- Cardiovascular disease is leading cause of NAFLD death